NYSE:LLY Eli Lilly and Company (LLY) Stock Price, News & Analysis $1,275.50 -31.19 (-2.39%) Closing price 10/23/2026 03:59 PM EasternExtended Trading$1,278.93 +3.43 (+0.27%) As of 10/23/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Eli Lilly and Company Stock (NYSE:LLY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Eli Lilly and Company alerts:Sign Up Key Stats Today's Range$1,257.62▼$1,307.9250-Day Range$1,115.53▼$1,308.2152-Week Range$809.63▼$1,321.21Volume2.27 million shsAverage Volume2.30 million shsMarket Capitalization$1.20 trillionP/E Ratio42.80Dividend Yield0.54%Price Target$1,317.93Consensus RatingModerate Buy Company Overview Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health. The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease. Lilly also develops medicines for migraine, depression and other neurological conditions, and maintains a pipeline of treatments in clinical development. Founded in 1876 by Colonel Eli Lilly, the company is headquartered in Indianapolis, Indiana. Lilly serves patients and healthcare providers through operations and commercial activities in numerous countries worldwide. David A. Ricks is the company’s chair and chief executive officer.AI Generated. May Contain Errors. Read More Eli Lilly and Company Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks94th Percentile Overall ScoreLLY MarketRank™: 4.70718010429 of 5 starsEli Lilly and Company scored higher than 94% of companies evaluated by MarketBeat, and ranked 10th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.7 / 5Analyst RatingModerate Buy Consensus RatingEli Lilly and Company has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 1 strong buy rating, 24 buy ratings, 3 hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Eli Lilly and Company is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageEli Lilly and Company has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Eli Lilly and Company's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth40.73% Earnings GrowthEarnings for Eli Lilly and Company are expected to grow by 40.73% in the coming year, from $33.56 to $47.23 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eli Lilly and Company is 41.49, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 35.48.Price to Earnings Ratio vs. SectorThe P/E ratio of Eli Lilly and Company is 41.49, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 204.23.Price to Earnings Growth RatioEli Lilly and Company has a PEG Ratio of 1.74. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioEli Lilly and Company has a P/B Ratio of 45.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Eli Lilly and Company's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.75% of the float of Eli Lilly and Company has been sold short.Short Interest Ratio / Days to CoverEli Lilly and Company has a short interest ratio ("days to cover") of 2.93, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Eli Lilly and Company has recently decreased by 6.44%, indicating that investor sentiment is improving significantly. Dividend3.3 / 5Dividend StrengthStrong Dividend YieldEli Lilly and Company has a dividend yield of 0.53%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthEli Lilly and Company has been increasing its dividend for 11 years.Dividend CoverageThe dividend payout ratio of Eli Lilly and Company is 23.22%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Eli Lilly and Company will have a dividend payout ratio of 14.65% next year. This indicates that Eli Lilly and Company will be able to sustain or increase its dividend.Read more about Eli Lilly and Company's dividend. News and Social Media4.3 / 5News Sentiment0.93 News SentimentEli Lilly and Company has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 102 news articles for Eli Lilly and Company this week, compared to 10 articles on an average week.Search Interest143 people have searched for LLY on MarketBeat in the last 30 days. This is an increase of 34% compared to the previous 30 days.MarketBeat Follows131 people have added Eli Lilly and Company to their MarketBeat watchlist in the last 30 days. This is an increase of 138% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Eli Lilly and Company insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,958,170.00 in company stock.Percentage Held by Insiders0.14% of the stock of Eli Lilly and Company is held by insiders.Percentage Held by Institutions82.53% of the stock of Eli Lilly and Company is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Eli Lilly and Company's insider trading history. Receive LLY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eli Lilly and Company and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LLY Stock News HeadlinesLilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 20263 hours ago | prnewswire.comGoldman Sachs rates Eli Lilly buy, lifts 12-month price target ahead of earningsOctober 23 at 8:23 PM | msn.comThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before they ever place a trade. This free guide from Base Camp Trading takes a different approach, starting with the basics and showing you exactly how options work, why traders use them, and how they fit into a simple trading plan. | Base Camp Trading (Ad)2 Growth Stocks to Hold for the Next Decade (Hint: These Aren't AI Stocks)October 23 at 3:45 PM | fool.com3 Stocks With Yields Big Enough to Make Election Volatility Easier to Stomach (LLY)Lincoln National, AbbVie and Phillips 66 offer dividends that pay investors through midterm volatility, backed by rising rates, steady drug demand and oil risk.October 23 at 7:25 AM | marketbeat.comTech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs (LLY)Biotech and pharma stocks, tracked by the iShares Biotechnology ETF, have shown relative strength amid the tech sell-off, with Eli Lilly and Pfizer standing out as top performers.October 20, 2026 | marketbeat.comThe AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are WinningAI-driven "biointelligence" is reshaping healthcare investing, with Guardant Health, Illumina, Eli Lilly and Moderna emerging as key stocks as data-driven testing, sequencing and therapies compound.October 19, 2026 | marketbeat.comWhat a Mixed Midterm Result Could Mean for These 2 Health Care ETFs (LLY)Polls suggest a divided government after the midterms, a scenario that historically benefits healthcare stocks. Here's how the XLV and IHF ETFs compare for investors eyeing the sector.October 19, 2026 | marketbeat.comSee More Headlines LLY Stock Analysis - Frequently Asked Questions How have LLY shares performed this year? Eli Lilly and Company's stock was trading at $1,075.00 at the beginning of 2026. Since then, LLY shares have increased by 18.7% and is now trading at $1,275.5030. How were Eli Lilly and Company's earnings last quarter? Eli Lilly and Company (NYSE:LLY) posted its quarterly earnings data on Wednesday, August, 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.40 by $1.98. Eli Lilly and Company's revenue for the quarter was up 47.7% compared to the same quarter last year. Read the conference call transcript. Is Eli Lilly and Company buying back stock? Eli Lilly and Company's board initiated a stock repurchase plan on Monday, December 9th 2024, which authorizes the company to repurchase $15,000,000,000 in shares, according to EventVestor. This means that the company could reacquire up to 2% of its stock through open market purchases. Stock buyback plans are typically an indication that the company's management believes its shares are undervalued. Does Eli Lilly and Company have any subsidiaries? Eli Lilly and Company subsidiaries include Protomer Technologies, Prevail Therapeutics Inc., Disarm Therapeutics, Disarm Therapeutics, Dermira, Loxo Oncology, CoLucid Pharmaceuticals, and others. Who are Eli Lilly and Company's major shareholders? Eli Lilly and Company's top institutional investors include Sapient Capital LLC (0.16%), Robeco Institutional Asset Management B.V. (0.09%), Assenagon Asset Management S.A. (0.08%) and Goelzer Investment Management Inc. (0.06%). Insiders that own company stock include Lilly Endowment Inc, David A Ricks, Daniel Skovronsky, J Erik Fyrwald, Patrik Jonsson, Johna Norton, Anat Hakim, Jamere Jackson, Gabrielle Sulzberger and Donald A Zakrowski. View institutional ownership trends. How do I buy shares of Eli Lilly and Company? Shares of LLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Eli Lilly and Company own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eli Lilly and Company investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Broadcom (AVGO), Micron Technology (MU), Johnson & Johnson (JNJ) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings8/05/2026Record date for 9/10 Dividend8/14/2026Ex-Dividend for 9/10 Dividend8/14/2026Dividend Payable9/10/2026Today10/24/2026Next Earnings (Estimated)10/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 LLY's financial health is in the Green zone, according to TradeSmith. LLY has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSE:LLY CIK59478 Webwww.lilly.com Phone(317) 276-2000Fax317-276-4878Employees50,000Year Founded1876Price Target and Rating Average Price Target for Eli Lilly and Company$1,317.93 High Price Target$1,600.00 Low Price Target$900.00 Potential Upside/Downside+3.3%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage29 Analysts Profitability EPS (Trailing Twelve Months)$29.80 Trailing P/E Ratio42.80 Forward P/E Ratio38.01 P/E Growth1.74Net Income$20.64 billion Net Margins33.53% Pretax Margin42.17% Return on Equity97.83% Return on Assets23.23% Debt Debt-to-Equity Ratio1.41 Current Ratio1.35 Quick Ratio1.00 Sales & Book Value Annual Sales$65.18 billion Price / Sales18.42 Cash Flow$24.54 per share Price / Cash Flow51.98 Book Value$28.07 per share Price / Book45.44Miscellaneous Outstanding Shares941,360,000Free Float940,039,000Market Cap$1.20 trillion OptionableOptionable Beta0.46 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NYSE:LLY) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | Sponsored$29.97 or $0 todayThe 0DTE Game Plan normally sells for 29.97, but it is free today through this link. Inside is a straightfo...Profits Run | SponsoredWATCH THIS BEFORE DECEMBER 8th!!James Altucher says a quiet government filing could reveal Elon Musk's biggest move yet, and almost nobody has...Paradigm Press | SponsoredMissed this in 2024? Here’s your second chanceIn April 2024, gold had gone nowhere for 13 years - then it surged to a record high, more than doubling in val...Traders Agency | SponsoredTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eli Lilly and Company Please log in to your account or sign up in order to add this asset to your watchlist. Share Eli Lilly and Company With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
